Cadrenal Therapeutics, Inc.
CVKDNasdaq
$2.16
↓ -7.3%Jul 17 close · end-of-day
Price
1Y↓ -80.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.2M
Enterprise Value
$2.9M
P/E
—
P/S
—
P/B
2.9
EV/EBITDA
—
PEG
—
FCF Yield
-242.4%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$11.9M
Free Cash Flow (TTM)
-$12.6M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-661.5%
ROIC
—
Debt / Equity
—
Net Cash
$2.3M
Return 1Y
-81.8%
Company profile
We are focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Our principal executive offices are located at 822 A1A North, Suite 306, Ponte Vedra, Florida.
- CEO
- Quang Pham
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Florida
- Website
- www.cadrenal.com
Management & directors
- Pham Quang XChairman, CEO and Interim CFO
- Szot Matthew KChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
CVKD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.04↓ -50.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$2.7M | -$7.6M | -$11.0M | -$13.5M |
| Net income | -$6.7M | -$8.4M | -$10.7M | -$13.2M |
| Diluted EPS | -$0.85 | -$9.29 | -$8.73 | -$6.64 |
| Operating cash flow | -$1.2M | -$3.5M | -$7.4M | -$12.6M |
| Free cash flow | -$1.2M | -$3.5M | -$7.4M | -$12.6M |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.5M | -$2.5M | -$4.3M | -$3.9M | -$3.7M | -$2.7M | -$3.1M | -$2.5M |
| Net income | -$2.4M | -$2.4M | -$4.2M | -$3.8M | -$3.7M | -$2.7M | -$3.0M | -$2.5M |
| Diluted EPS | -$2.24 | -$2.18 | -$2.75 | -$2.09 | -$1.87 | -$1.31 | -$1.37 | -$1.04 |
| Operating cash flow | -$1.5M | -$2.2M | -$1.8M | -$4.6M | -$3.0M | -$2.4M | -$2.6M | -$3.0M |
| Free cash flow | — | — | — | -$4.7M | -$3.0M | -$2.4M | -$2.6M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-29 | Pham Quang X· Chairman and CEO | Sale | 7,400 | $3.03 | $22,422.00 | filing |
| 2026-06-26 | Pham Quang X· Chairman, CEO and Interim CFO | Sale | 9,029 | $3.05 | $27,538.45 | filing |
| 2026-06-25 | Pham Quang X· Chairman, CEO and Interim CFO | Sale | 2,127 | $3.00 | $6,381.00 | filing |
| 2026-06-23 | Pham Quang X· Chairman, CEO and Interim CFO | Sale | 2,277 | $3.20 | $7,286.40 | filing |
| 2026-06-22 | Pham Quang X· Chairman, CEO and Interim CFO | Sale | 9,167 | $3.55 | $32,542.85 | filing |
| 2026-06-17 | Pham Quang X· Chairman, CEO and Interim CFO | Sale | 513 | $3.16 | $1,621.08 | filing |
| 2026-06-16 | Pham Quang X· Chairman, CEO and Interim CFO | Sale | 3,613 | $3.18 | $11,489.34 | filing |
| 2026-06-15 | Pham Quang X· Chairman, CEO and Interim CFO | Sale | 3,666 | $3.58 | $13,124.28 | filing |
| 2026-06-12 | Pham Quang X· Chairman, CEO and Interim CFO | Sale | 12,996 | $3.94 | $51,204.24 | filing |
| 2026-06-11 | Pham Quang X· Chairman, CEO and Interim CFO | Sale | 1,462 | $4.12 | $6,023.44 | filing |
| 2026-06-10 | Pham Quang X· Chairman, CEO and Interim CFO | Sale | 3,500 | $4.21 | $14,735.00 | filing |
| 2026-06-09 | Pham Quang X· Chairman, CEO and Interim CFO | Sale | 12,992 | $4.06 | $52,747.52 | filing |
| 2026-06-08 | Pham Quang X· Chairman, CEO and Interim CFO | Sale | 5,893 | $4.38 | $25,811.34 | filing |
| 2026-06-05 | Pham Quang X· CEO and Chairman | Sale | 2,064 | $4.42 | $9,122.88 | filing |
| 2026-06-04 | Pham Quang X· CEO and Chairman | Sale | 3,898 | $4.41 | $17,190.18 | filing |
| 2026-06-03 | Pham Quang X· CEO and Chairman | Sale | 2,323 | $4.26 | $9,895.98 | filing |
| 2026-06-02 | Pham Quang X· CEO and Chairman | Sale | 349 | $4.46 | $1,556.54 | filing |
| 2026-05-29 | Pham Quang X· CEO and Chairman | Sale | 303 | $5.01 | $1,518.03 | filing |
| 2026-05-28 | Pham Quang X· CEO and Chairman | Sale | 2,989 | $4.93 | $14,735.77 | filing |
| 2026-05-22 | Pham Quang X· CEO and Chairman | Sale | 1,165 | $5.69 | $6,628.85 | filing |
| 2026-05-12 | Pham Quang X· CEO and Chairman | Sale | 3,298 | $5.28 | $17,413.44 | filing |
| 2026-05-11 | Pham Quang X· CEO and Chairman | Sale | 6,476 | $5.76 | $37,301.76 | filing |
| 2025-12-29 | Szot Matthew K· Chief Financial Officer | Sale | 9,933 | $6.97 | $69,233.01 | filing |
| 2025-10-27 | Szot Matthew K· Chief Financial Officer | Sale | 1,800 | $13.99 | $25,182.00 | filing |
| 2025-10-27 | Pham Quang X· CEO and Chairman | Sale | 1,315 | $13.99 | $18,396.85 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.